A5103149255- Bone health and treatments
- Estrogen and related hormone effects
- Bone health and osteoporosis research
- Breast Cancer Treatment Studies
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Bone Metabolism and Diseases
- Management of metastatic bone disease
- Cancer Risks and Factors
- Bone and Joint Diseases
- Prostate Cancer Treatment and Research
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Medication Adherence and Compliance
- Menopause: Health Impacts and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Medical Imaging and Pathology Studies
- Medical Imaging Techniques and Applications
- PI3K/AKT/mTOR signaling in cancer
- Bone fractures and treatments
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
Cardiovascular Center Frankfurt
2019-2024
Philipps University of Marburg
2013-2023
Philips (Germany)
2019-2023
Krankenhaus Nordwest
2014-2021
Heidelberg University
2000-2019
Universität Hamburg
2000-2019
University Hospital Heidelberg
2013-2019
University Medical Center Hamburg-Eppendorf
2018-2019
University Hospital Ulm
2018-2019
Marienhospital Bottrop
2018-2019
Denosumab is a fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL, key mediator of osteoclast formation, function, and survival. This phase 3, multicenter, doubleblind study compared the efficacy safety denosumab with alendronate in postmenopausal women low mass. One thousand one hundred eighty-nine T-score <or= -2.0 at lumbar spine or total hip were randomized 1:1 to receive subcutaneous injections (60 mg every 6 mo [Q6M]) plus oral placebo weekly (n = 594)...
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in across tumour types and should part standard treatment.•Treatment-induced loss increases fracture risk may require use a bone-targeted agent addition to lifestyle modifications.•The bisphosphonate adjuvant therapies postmenopausal early breast reduces recurrence improves survival.
In addition to classic tumor-related prognostic factors, patient characteristics may be associated with breast cancer outcome.To assess the association between age at diagnosis and outcome in postmenopausal women hormone receptor-positive cancer.Study analysis of 9766 patients enrolled TEAM (Tamoxifen Exemestane Adjuvant Multinational) randomized clinical trial January 2001 2006. Age was categorized as younger than 65 years (n=5349), 74 (n=3060), 75 or older (n=1357).Primary end point...
Abstract Learning Objectives After reading this article, the reader should be able to: Monitor for and treat to prevent bone loss in postmenopausal breast cancer patients receiving an aromatase inhibitor.Describe methodology of Z-FAST ZO-FAST clinical trials.Discuss effectiveness tolerability zoledronic acid when administrated associated with inhibitors. CME This article is available continuing medical education credit at CME.TheOncologist.com Background. The interim (12-month) results two...
Progress has been made in the treatment of metastatic breast cancer recent decades, but very few therapies use patient or tumor-specific characteristics to tailor individualized treatment. More than ten years after publication reference human genome sequence, analysis methods have improved enormously, fostering hope that biomarkers can be used individualize and offer precise based on tumor characteristics. Biomarkers at every level system (genetics, epigenetics, gene expression, micro-RNA,...
The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer.
Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in susceptibility genes and clinical relevance these are unclear. In this study, a prospective cohort mBC was used to determine mutation rates for (BC) predisposition genes, evaluate characteristics mutations, assess influence on patient outcome.
BackgroundBreast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor–positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits adding everolimus to exemestane. Moreover, preclinical studies, mammalian target rapamycin inhibition was associated decreased osteoclast survival and activity. Exploratory analyses BOLERO-2 evaluated the effect on bone marker levels...